The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).
Hiroshige Yoshioka
Honoraria - AstraZeneca
Tetsuya Mitsudomi
Honoraria - AstraZeneca
Satoshi Morita
Honoraria - AstraZeneca
Yasushi Yatabe
Honoraria - DAKO; Leica Biosystems; Pfizer; Roche; Ventana
Shunichi Negoro
No relevant relationships to disclose
Isamu Okamoto
No relevant relationships to disclose
Takashi Seto
Honoraria - AstraZeneca; Sanofi
Research Funding - AstraZeneca
Miyako Satouchi
Honoraria - AstraZeneca; Sanofi
Hirohito Tada
No relevant relationships to disclose
Tomonori Hirashima
No relevant relationships to disclose
Kazuhiro Asami
No relevant relationships to disclose
Nobuyuki Katakami
Honoraria - AstraZeneca; Sanofi
Minoru Takada
No relevant relationships to disclose
Kazuhiko Shibata
No relevant relationships to disclose
Shinzoh Kudoh
Research Funding - Kyowa Hakko Kirin
Eiji Shimizu
No relevant relationships to disclose
Hiroshi Saito
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Shinichi Toyooka
Honoraria - AstraZeneca
Kazuhiko Nakagawa
Honoraria - AstraZeneca; Sanofi
Research Funding - AstraZeneca; Sanofi
Masahiro Fukuoka
No relevant relationships to disclose